Cantuzumab mertansine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cantuzumab mertansine
Mertansine mab structure.svg
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target MUC1
Clinical data
ATC code
  • none
CAS Number
  • none
 NYesY (what is this?)  (verify)

Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer.[1] It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1).[2] It was developed by ImmunoGen.


After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.[3]

Clinical trials[edit]

Three phase I clinical studies had reported results by 2003.[4] By 2005, clinical development had been suspended.[5]

See also[edit]


  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Cantuzumab mertansine, American Medical Association.[dead link]
  2. ^ Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Rodon et al. 2008
  3. ^ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004
  4. ^
  5. ^